Digestive decontamination in burn patients: A systematic review of randomized clinical trials and observational studies

Objective

The objective of this systematic review is to assess the effect of selective digestive decontamination (SDD) or non-absorbable enteral antibiotics (EA) on mortality, the incidence of infection and its adverse effects in burn patients.

Non-invasive ventilation for weaning, avoiding reintubation after extubation and in the postoperative period: a meta-analysis

Non-invasive ventilation (NIV) is a supportive therapy that improves mortality in acute respiratory failure (RF). It may also be used in patients recently extubated in intensive care units (ICUs), after operation, and to aid weaning from mechanical ventilation (MV) by reducing the morbidity and mortality associated with further MV. A meta-analysis of the available evidence was performed on the use of NIV in three areas: weaning, reduction in reintubation rates post-extubation on ICU, and reduction in RF after major surgery. Sixteen relevant randomized controlled trials were identified by three reviewers after a detailed search of identified medical databases. A meta-analysis of summary statistics relating to predetermined endpoints (ICU and hospital length of stay, ICU and hospital mortality, reintubation, pneumonia) was performed. NIV reduced the ICU length of stay when used for weaning (5.12 days) and post-surgery (0.44 days). NIV reduced reintubation rates post-surgery [odds ratio (OR) 0.24, 95% confidence interval (CI) 0.12-0.50] and the incidence of pneumonia in weaning (OR 0.12, 95% CI 0.05-0.31) and post-surgery (OR 0.27, 95% CI 0.09-0.77). There was insufficient evidence to suggest that NIV improves ICU survival, but an increased hospital survival in weaning (OR 0.55, 95% CI 0.31-0.98) and post-surgery (OR 4.54, 0.95% CI 1.35-15.31) was seen. A meta analysis of NIV use in selected subgroups of recently extubated patients suggests that the judicious NIV use may reduce ICU and hospital length of stay, pneumonia, and reintubation rates and hospital survival.     

Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 8. Efficacy and safety of recombinant human activated protein C for severe sepsis.

Objective: To find out whether activated recombinant protein C reduces the death rate from all causes at 28 days among patients with severe sepsis. Design: A randomized, double-blind, placebo-controlled trial. Setting: Multicentre; 164 centres in 11 countries. Patients: The study comprised 1690 patients (840 in the control group and 850 in the treatment group) who had known or suspected infection based on clinical data, plus 3 or more signs of systemic inflammation and sepsis-induced organ dysfunction for at least 24 hours. Intervention: Patients were randomized to intravenous infusion of drotrecogin α activated (24 μg/kg body weight hourly) for a total of 96 hours or placebo. Main outcome measure: Death from any cause at 28 days. Results: The death rate in the treatment group was 24.7% (95% confidence interval [CI] 22%–28%) and in the control group was 30.8% (95% CI 28%–34%). Treatment with activated protein C was associated with a reduction in the relative risk of death of 19.4% (95% CI 6.6%–30.5%) and absolute reduction in the risk of death of 6.1% (p = 0.005). Serious bleeding occurred in 3.5% of patients in the drotrecogin α activated group compared with 2.0% in the placebo group (p = 0.06). Conclusion: Treatment with activated protein C significantly reduces mortality (6.1% absolute reduction) with severe sepsis but may be associated with an increased risk of bleeding (treatment group 3.2%, p = 0.06).     

MRSA colonization and acquisition in the burn unit: A systematic review and meta-analysis

BackgroundMethicillin-resistant Staphylococcus aureus (MRSA) is one of the most commonly encountered bacteria in the burn unit. In order to investigate the magnitude of this challenge, we assessed the prevalence of MRSA colonization on admission and the incidence of MRSA acquisition within burn units.MethodsWe searched PubMed and EMBASE for studies reporting MRSA colonization among patients admitted in burn units.ResultsWe identified 16 articles that fulfilled our inclusion criteria and found an overall pooled prevalence of MRSA colonization upon the first 72 h of admission (colonization on admission) to the burn unit of 4.1% (95% CI: 2.7%–5.7%). MRSA acquisition in studies without a decolonization protocol was 21.2% (95% CI: 13.2%–30.5%) with a statistically significant downward trend over the years. Studies that implemented a decolonization protocol yielded a MRSA acquisition incidence rate of 4.5% (95% CI: 0.9%–10.6%). MRSA acquisition was higher among patients that have had inhalation injury (OR 3.96, 95% CI: 2.51–6.23), flame burns (OR 1.85, 95% CI: 1.25–2.73), or ICU admission (OR 3.12, 95% CI: 2.18–4.47).ConclusionOur study yielded that among burn victims, MRSA colonization prevalence on admission is not negligible and the risk of becoming MRSA colonized during hospitalization is higher when no decolonization protocols are implemented. Flame burns, admission to ICU, and inhalation injury were found to be associated with MRSA acquisition.     

Closed tracheal suction systems for prevention of ventilator-associated pneumonia

We have assessed the evidence that closed tracheal suction systems (TSS) prevent ventilator-associated pneumonia (VAP), using a meta-analysis of randomized controlled trials (RCTs). We searched PubMed and Cochrane databases to identify RCTs that compared closed with open TSS for the management of mechanically ventilated (MV) patients. Nine RCTs were included in the meta-analysis. There was no difference in the incidence of VAP between patients managed with closed and open TSS [odds ratio (OR)=0.96, 95% confidence intervals (CI) 0.72-1.28]. There was no heterogeneity among the eligible trials (I2=0, 95% CI 0-0.65). The compared groups did not differ with respect to mortality (OR=1.04, 95% CI 0.78-1.39) or intensive care unit (ICU) length of stay [two RCTs: 12.3 (sd 1.1) vs 11.5 (1.4) days and 15.6 (13.4) vs 19.9 (16.7) days]. Suctioning with closed systems was associated with longer MV duration (weighted mean differences: 0.65 days, 95% CI 0.28-1.03) and higher colonization of the respiratory tract (OR=2.88, 95% CI 1.50-5.52) than open TSS. The available evidence suggests that closed as opposed to open TSS usage did not provide any benefit on VAP incidence, mortality, or ICU stay of MV patients.     

Effects of Human Recombinant Growth Hormone on Donor-site Healing in Burned Adults

Patients suffering severe burns have an accelerated catabolism with a highly negative nitrogen balance that may worsen their prognosis. Somatropin treatment has been shown to improve this balance in different hypercatabolic situations. Moreover, in children with extensive burns it also reduces the healing time of the skin graft donor site and shortens the hospital stay. In the existing literature there are no controlled prospective clinical trials in adult patients that confirm these data. Our aim was to demonstrate the efficacy of recombinant growth hormone (somatropin) in reducing the healing time of the skin graft donor sites and the length of stay in the burn unit in adult patients with severe burns. A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 adult patients with severe burns (more than 40% of the total body surface burned or more than 15% full-thickness burns). Patients received placebo (n = 11) or somatropin (n = 13) at a dosage of 0.15 mg/kg/day divided into two equal doses (every 12 hours) via intramuscular injection. Treatment was initiated the day the first autograft was performed and terminated the day the patient was discharged from the burn unit. The mean number (+/- SD) of skin grafts per patient was similar between the two groups (4.2 +/- 1.8 vs 3.4 +/- 1.8 in the placebo and somatropin groups, respectively). No reduction in the healing time of the skin graft donor site was observed in the somatropin group compared to the placebo group. Likewise, the time admitted to the burn unit was not significantly different, either in the absolute number of days (36.2 +/- 19.7 vs 30.1 +/- 16.8 days in the placebo and somatropin groups, respectively) or in relation to the percentage of the total body surface burned or the body surface with full-thickness burns. Growth hormone and insulin-like growth factor I (IGF-I) levels were three and five times higher, respectively, in the somatropin group than in the placebo group. Ten of the patients treated with somatropin experienced hyperglycemia, and seven of them required insulin treatment. No other adverse side effect was observed. One patient in the placebo group died as a result of sepsis and multiple organ failure. Somatropin, with the treatment regimen and dosage used in these studies, did not reduce the healing time of the skin graft donor sites or the length of hospitalization in the burn unit in adult patients with severe burns.     

Impact of inhalation injury on outcomes in critically ill burns patients: 12-year experience at a regional burns centre

IntroductionBurns inhalation injury increases the attributable mortality of burns related trauma. However, diagnostic uncertainties around bronchoscopically graded severity, and its effect on outcomes, remain. This study evaluated the impact of different bronchoscopic burns inhalation injury grades on outcomes.MethodsA single-centre cohort study of all patients admitted to the London Burns centre intensive care unit (BICU) over 12 years. Demographic data, burn and burns inhalation injury characteristics, and ICU-related parameters were collected retrospectively. The primary outcome was mortality. Secondary outcomes were hospital and ICU lengths of stay. The impact of pneumonia was determined. Univariate and multivariable Cox’s proportional hazards regression analyses informed factors predicting mortality.ResultsBurns inhalation injury was diagnosed in 84 of 231 (36%) critically ill burns patients; 20 mild (grade 1), 41 severe (grades 2/3) and 23 unclassified bronchoscopically. Median (IQR) total body surface area burned (TBSA) was 20% (10?40). Mortality was significantly higher in patients with burns inhalation injury vs those without burns inhalation injury (38/84 [45%] vs 35/147 [24%], p < 0.001). Patients with pneumonia had a higher mortality than those without (34/125 [27%] vs 8/71 [11%], p = 0.009). In multivariable analysis, severe burns inhalation injury significantly increased mortality (adjusted HR=2.14, 95%CI: 1.12–4.09, p = 0.022), compared with mild injury (adjusted HR=0.58, 95% CI: 0.18–1.86, p = 0.363). Facial burns (adjusted HR=3.13, 95%CI: 1.69–5.79, p < 0.001), higher TBSA (adjusted HR=1.05, 95%CI: 1.04–1.06, p < 0.001) and older age (adjusted HR=1.04, 95%CI: 1.02–1.07, p < 0.001) also independently predicted mortality, though pneumonia did not.ConclusionsSevere burns inhalation injury is a significant risk factor for mortality in critically ill burns patients. However, pneumonia did not increase mortality from burns inhalation injury. This work confirms prior implications of bronchoscopically graded burns inhalation injury. Further study is suggested, through registries, into the diagnostic accuracy and reliability of bronchoscopy in burns related lung injury.     

Selective decontamination of the digestive tract in severely burned pediatric patients.

Infection is still one of the leading causes of morbidity and mortality in severely burned patients. Evidence suggests that many of the responsible organisms are endogenous. Systemic antibiotic prophylaxis is not effective, and produces resistant strains of microorganisms. SDD has been postulated to be beneficial for controlling and decreasing infections in critically ill patients. Its efficacy in severely burned patients, however, remains controversial. In order to analyze the efficacy of selective decontamination of the digestive (SDD) tract, to decrease the bacterial colonization of the aerodigestive tract and burn wounds, and the incidence of septic complications in severely burned children, 23 pediatric patients affected of severe burns were prospectively randomized in a double-blinded study. Eleven patients received SDD (Polymyxin E, Tobramycin, and Amphotericin B), and 12 placebo. Demographics, hospital course, microbiology results, complications, infectious episodes, and serum levels of IL-1beta, IL-6, IL-10, and TNF-alpha were compared to determine the efficacy of SDD. Colonization rates to the wound, sputum, nasogastric aspirates, and feces were similar. Pneumonia, sepsis and other complications had similar incidence in both groups. Serum levels of all cytokines studied were also comparable, suggesting a similar inflammatory status in all patients, regardless of the treatment received. Patients in the SDD group, however, had a significantly higher incidence of diarrhea (P=0.003). We can conclude that selective decontamination of the digestive tract with Polymixin E, Tobramycin and Amphotericin B is not effective to decrease bacterial colonization and infectious episodes in severely burned pediatric patients.     

Self-inflicted burns, outcome and cost

INTRODUCTION: Self-inflicted burns represent a small number of total admissions to a burns unit, yet they constitute a major workload. METHODS: A retrospective analysis of self-inflicted burns admitted between 1998 and 2002. RESULTS: One thousand six hundred and fifty six patients were admitted with acute burn injuries, of these 56 were self-inflicted. 24 patients had a previous history of self-harming and 22 were unemployed. History of a psychiatric illness was found in 46 patients. Flames caused 46 out of 56 injuries. Mean total body surface area (TBSA) was 27%. Approximately 39% needed admission to intensive care unit (ICU). The mortality rate was 25%. On discharge, 29% of the patients re-self harmed. CONCLUSION: Self-inflicted burns have a poorer outcome. Improving the psychiatric and social support can reduce the incidence of self-harming behaviour, its repetitiveness and subsequently the cost of burn care.     

Treatment outcome of selective digestive decontamination and enteral nutrition in patients with severe acute pancreatitis

Background/Purpose Sepsis due to infected pancreatic necrosis is the most serious complication in the late phase of severe acute pancreatitis (SAP). Bacterial translocation from the gut is thought to be the main cause of pancreatic infection. The possibility has recently been reported that selective digestive decontamination (SDD) and enteral nutrition (EN) may alleviate the complications and reduce the mortality rate in patients with SAP. We analyzed the treatment outcome of SDD and EN in patients with SAP. Methods We divided 90 patients with SAP into three groups: SDD(−)EN(−),group A; SDD(+)EN(−), group B; and SDD(+)EN(+), group C. Clinical outcome was analyzed retrospectively. The effect of SDD was compared in groups A and B, and the effect of EN was compared in groups B and C. Results The background of patients was not significantly different between the groups. SDD reduced the incidence of organ dysfunction (from 70% to 59%) and the mortality rate (from 40% to 28%), but the differences were not significant. EN reduced the incidence of infected pancreatic necrosis (from 31% to 24%) and the frequency of surgery for pancreas (from 28% to 18%), and further reduced the mortality rate (from 28% for SDD to 16%), but the differences were not significant. The peripheral lymphocyte count was significantly increased in patients with EN. Conclusions SDD and EN did not significantly affect the treatment outcome in SAP. However, the results in this study raise the possibility that SDD and EN may decrease the complications and reduce the mortality rate in SAP. The efficacy of SDD and EN for SAP should be evaluated in a randomized controlled trial.     

Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study

BACKGROUND: There is significant morbidity and mortality related to fungal infections in the solid-organ transplant population. METHODS: A prospective, randomized, double-blind, placebo-controlled, restricted sequential design trial was performed in 71 adults undergoing orthotopic liver transplantation. Patients were randomly assigned to receive either itraconazole (5.0 mg/kg orally, preoperatively, 2.5 mg/kg orally, two times a day, postoperatively) or placebo. Therapy continued for a maximum of 56 days or until patient was discharged from hospital or met a predefined endpoint. Measurements included incidence of fungal colonization, superficial or systemic fungal infections requiring systemic therapy, adverse events, and mortality rate. RESULTS: This trial design supported the superiority of itraconazole in preventing fungal infections; nine patients in the placebo group (24%; 95% confidence interval, 0.118-0.412) and one patient in the itraconazole group (4%; 95% confidence interval, 0.001-0.204) developed fungal endpoints requiring therapy with amphotericin B (P=0.04, Fisher's exact test). At the time of enrollment, fungal colonization occurred in 40% and 37% of itraconazole and placebo patients (P=0.43), respectively. Adverse events were reported by 97% and 100% of the intraconazole and placebo groups, respectively, and one itraconazole and six placebo-group patients died within the study period. There was no relation to trial medication for serious adverse events. CONCLUSION: Prophylaxis with itraconazole reduces fungal infections in patients undergoing orthotopic liver transplantation and is well tolerated.     

The impact of combined trauma and burns on patient mortality

BACKGROUND: Combined trauma and burn injuries are uncommon and seldom studied. There is a presumption that these patients fare worse than their trauma- and burn-only counterparts, but the mortality risk has not been quantified. METHODS: This was a retrospective cohort study using the 1994 to 2002 National Trauma Data Bank. Trauma- and burn-only patients were categorized according to Injury Severity Score (ISS) and burn severity (percentage body surface area burned [BSAB]), respectively, and combined trauma-burn patients were similarly categorized. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated comparing combined trauma-burn mortality to trauma-only and burn-only patients by corresponding trauma or burn severity. RRs were adjusted for age, gender, and ISS or burn severity. RESULTS: Compared with minor trauma-only patients (ISS of 1-15), patients with minor trauma, when combined with burn injury, had significantly increased mortality (RR, 4.04; 95% CI, 3.51-4.66). Similarly, relative to minor burn-only patients (BSAB of 1-25%), combined trauma-burn patients with minor burns (RR, 5.00; 95% CI, 3.54-7.06) had significantly increased mortality. For combined trauma-burn patients with more severe burns or trauma, small but significant increased mortality risks were seen relative to major trauma-only patients (ISS of 26+; RR, 1.26; 95% CI, 1.05-1.51) and major burn-only patients (BSAB of 76+; RR, 1.45; 95% CI, 1.15-1.82). CONCLUSION: The large increased risk of death for those with combined minor injuries is of clinical interest because the majority of combined patients fall into this category. Future research should characterize specific causes and types of injury of increased mortality in the patient with combined injuries.     

气管切开时机对长期机械通气患者预后影响的meta分析

目的 评价气管切开时机对长期机械通气患者预后的影响.方法 通过计算机检索Pubmed、Embase、The Cochrane Library数据库和中国生物医学文献数据库(CBM)并联合手工检索,收集1990年1月至2010年6月关于气管切开时机对长期机械通气患者预后影响的随机对照研究(RCT),并对收集的RCT进行评...     

Paediatric ICU burns in Finland 1994-2004

INTRODUCTION: The paediatric burn population requiring intensive care in Finland has never been examined before. The aim of this study was firstly to determine the aetiology, incidence and prognosis of paediatric burns requiring intensive care in Finland and secondly to compare the possible differences between the two national burn centres. METHODS: All burn patients' charts were retrospectively reviewed in two national burn centres from an 11-year-period. Patients whose ICU stay was more than 48h, were included. RESULTS: Forty-five children who were hospitalized in the two burn centres during the study period met the inclusion criteria. They represent 2.4% (45/1898) of all burns victims hospitalized in these burn centres during that time giving an incidence of 0.1/100,000 per year in Finland. The median age was 5 years, every third patient was 0-2 years old and 75.6% were male. Most burns were scalds (42.2%), which caused all burns (100%) in age group 0-2 years. Flame burns were most frequent (83%) in the age group 6-10 years. In the 11-16 years old patients, high voltage/electric burns caused 50% of all burns and flame the other 50%. The overall median TBSA in all burns was 26%. The median (range) hospital stay was 12 days (2-193) (0.88 days/% burned) and the median (range) ICU days was 7 (2-64) (0.29 days/%). Intubation and respirator therapy was needed in 31 (46%) patients. There were no patients who needed haemofiltration or haemodialysis and no mortality. Only six patients (13%) were treated conservatively and 39 (87%) surgically. Dressing changes under general anaesthesia were preferred in Helsinki (37 times) and especially in the paediatric hospital (32 times) compared to Kuopio (7 times). Allografts were used only in Helsinki in 4 patients whereas artificial skin was used only in Kuopio in 15 patients. The overall cost of care was very similar in both centres being 1292-1425 euros per hospital day. CONCLUSIONS: There were some small differences between the two burn centres in treatment policies. Most patients were male and most common aetiology was scald. The prognosis of these patients was excellent with no mortality.     

Endovascular vs open repair of acute abdominal aortic aneurysms--a systematic review and meta-analysis

OBJECTIVE: To compare the results of emergency open repair of acute (ruptured or symptomatic intact) abdominal aortic aneurysms with that of endovascular repair. METHODS: A systematic literature search was performed to identify series that reported comparative outcomes. PubMed, Embase, the randomized controlled trial (RCT) register, and all relevant major journals were searched independently by two researchers. The outcome measures were 30-day mortality, intensive care unit (ICU) stay, hospital stay, blood loss, and operative time. RESULTS: Twenty-three studies were identified. Of these, only one was a randomized controlled trial, which is now halted. The total number of patients in the pooled data was 7040 (730 emergency endovascular aneurysm repair [eEVAR]). Emergency EVAR was associated with a significant reduction in mortality (pooled odds ratio 0.624; 95% confidence interval [CI] 0.518 to 0.752; P < .0001). The eEVAR group's ICU stay was reduced by 4 days (pooled effect size estimate -0.70; 95% CI -1.05 to -0.35; P < .0001) and hospital stay with eEVAR was reduced by 8.6 days (pooled effect size estimate -0.33; 95% CI -0.50 to -0.16; P = .0001). In addition, eEVAR was also associated with a significant reduction in blood loss (pooled effect size estimate -1.88 liters; 95% CI -2.49 to -1.27; P < .0001) and reduced procedure time (pooled effect size estimate -0.65; 95% CI -0.95 to -0.36; P < .0001). CONCLUSION: This meta-analysis suggests benefits to the selected group of patients undergoing this minimally invasive procedure. There is a reduction in the high mortality, prolonged intensive care requirement and total hospital stay, which are historically associated with open repair. It also indicates that most patients are fit enough to undergo computerized tomography (CT) scanning in acute settings. However, because of heterogeneity and bias in the outcomes these results should be interpreted with caution.     

重组人生长激素影响重度烧伤患者预后的前瞻性多中心研究

目的观察重组人生长激素(rhGH)对重度烧伤患者预后的影响。方法采用前瞻性多中心随机对照临床试验,将207例成年重度烧伤患者随机分为治疗组(每日皮下注射rhGH)和对照组(同法注射等量等渗盐水),观察两组患者病死率、血糖变化和烧伤脓毒症发生情况。结果治疗组和对照组的病死率分别为0.89%、5.26%(P>0.05),高血糖发生率分别为36.61%、18.95%(以>10.00mmol/L为标准),差异有统计学意义(P<0.01),两组患者脓毒症发生率比较差异无统计学意义(P>0.05).结论适量rhGH在成年重度烧伤患者中应用是安全的,但需注意观察血糖的变化。     

Validation of predictive rules and indices of severity for community acquired pneumonia

BACKGROUND: A study was undertaken to validate the modified American Thoracic Society (ATS) rule and two British Thoracic Society (BTS) rules for the prediction of ICU admission and mortality of community acquired pneumonia and to provide a validation of these predictions on the basis of the pneumonia severity index (PSI). METHOD: Six hundred and ninety six consecutive patients (457 men (66%), mean (SD) age 67.8 (17.1) years, range 18-101) admitted to a tertiary care hospital were studied prospectively. Of these, 116 (16.7%) were admitted to the ICU. RESULTS: The modified ATS rule achieved a sensitivity of 69% (95% CI 50.7 to 77.2), specificity of 97% (95% CI 96.4 to 98.9), positive predictive value of 87% (95% CI 78.3 to 93.1), and negative predictive value of 94% (95% CI 91.8 to 95.8) in predicting admission to the ICU. The corresponding predictive indices for mortality were 94% (95% CI 82.5 to 98.7), 93% (95% CI 90.6 to 94.7), 49% (95% CI 38.2 to 59.7), and 99.5% (95% CI 98.5 to 99.9), respectively. These figures compared favourably with both the BTS rules. The BTS-CURB criteria achieved predictions of pneumonia severity and mortality comparable to the PSI. CONCLUSIONS: This study confirms the power of the modified ATS rule to predict severe pneumonia in individual patients. It may be incorporated into current guidelines for the assessment of pneumonia severity. The CURB criteria may be used as an alternative tool to PSI for the detection of low risk patients.     

Effectiveness of topical selective decontamination, without systemic antibiotic prophylaxis, in prevention of pulmonary infection in intensive care

Forty-seven patients admitted in our general ICU and treated with Selective Digestive Decontamination (SDD) without any systemic antibiotic prophylaxis, were prospectively studied and compared with an historical group of 50 non treated subjects. The 2 groups were no different as to underlying disease, age, sex and prognostic index (SAPS). In the treated group was recorded an important and statistically significant reduction in the incidence of pneumonia and in the frequency of pulmonary infections caused by enterobacteriaceae and pseudomonceae. Gram-positive identification in tracheal aspirates was not significantly different in the two groups as well as the incidence of "early pneumonia". In the treated group, a sharp decrease of the total amount of fever-days through ICU stay was observed. The antibiotic consumption resulted to be an overall 28.3% lower in the group treated with, SDD with particular regard to broad-spectrum ones.     

Efficacy and safety of haloperidol for delirium prevention in adult patients: An updated meta-analysis with trial sequential analysis of randomized controlled trials

Study objectiveTo identify the efficacy and safety of haloperidol prophylaxis in adult patients with a high risk for delirium.DesignA meta-analysis with trial sequential analysis of randomized controlled trials.InterventionA comprehensive search was performed in PubMed, the ISI Web of Knowledge, the Cochrane Library, and Embase databases from inception through to March 2019.Citation screening, data abstraction and quality assessment were performed in duplicate. Meta-analysis with trial sequential analysis (TSA) were used to assess the primary and secondary outcomes. In addition, we used the Grading of Recommendations Assessment Development and Evaluation (GRADE) to evaluate the certainty of the body of evidence.Main resultsWe appraised 8 RCTs involving 3034 patients that that were in compliance with inclusion and exclusion criterion. Pooled analyses indicated patients receiving haloperidol prophylaxis and placebo or normal saline did not significantly differ in incidence of delirium (relative risk [RR] = 0.90, 95% confidence interval [CI] = 0.70 to 1.15), with TSA inconclusive. Notably, compared with the control group, use of haloperidol significantly decreased the duration of delirium (Mean difference [MD] −0.94; 95% CI −1.82 to −0.06 days), with a marked heterogeneity. Additionally, haloperidol prophylaxis does not significantly affect duration of mechanical ventilation, length of intensive care unit (ICU) stay, length of hospital stay and mortality. In terms of safety profiles, haloperidol was not associated with increased risk for QTc prolongation, extrapyramidal symptoms, or adverse events. GRADE indicated the level of evidence was very low for a benefit from haloperidol prophylaxis.ConclusionsThe results of our meta-analysis suggested the use of prophylactic haloperidol compared with placebo had no beneficial impacts on incidence of delirium, duration of mechanical ventilation, length of intensive care unit (ICU) stay, length of hospital stay and mortality in adult patients. It appeared to have a positive effect on duration of delirium, while with a significant heterogeneity. These findings do not support the routine usage of haloperidol for delirium prevention.Trial registration: PROSPERO registration number: CRD42018100511. Registered on 17 July 2018.     

Décontamination digestive sélective chez le malade de réanimation

Nosocomial infections increase morbidity and mortality in hospitalized patients. ICU patients are at high risk of sustaining them, due to the high rate of invasive procedures and their poor health state. Conventional methods for decreasing the incidence of infection in ICU patients include hand-washing, catheter care, strict antibiotic policy, and reduction of environmental sources of infection. Despite these measures, the colonization in these patients is always high, because of the presence of pathogens in the own patients' flora. Nosocomial pneumonia which is a major cause of mortality in ICU patients arises from retrograde colonization of the lung by pathogens originating from oro-pharyngeal and gastric secretions. Since 1984, selective decontamination of the digestive tract (SDD) has been advocated in ICUs to prevent from bacterial and fungal gastrointestinal/oropharyngreal colonization, nosocomial infection, subsequent multiple organ failure (MOF) and death.The SDD regimen is usually an extemporaneously prepared suspension of antimicrobial agents. Appropriate antibiotics for this regimen should ideally be nonabsorbable, to prevent from the development of resistant pathogens and avoid systemic toxicity. They should also be able to selectively eliminate enterobacteriaceae and yeasts, without decreasing the protective anaerobic flora. The most used combination is a suspension of colistin, amphotericin B and aminoglycoside, administered four times day through the nasogastric tube, in association with a paste consisting of 2 p. 100 colistin/amphotericin B/aminoglycoside, applied to the oropharynx. A parenteral antibiotic is also often co-administered during the first four days to prevent from early infections until the SDD regimen reachies its full effect ; cefotaxime is usually used for this. SDD significantly decreases colonization rates in the oropharynx, gastrointestinal (GI) tract and trachea. This effects is primarily attributable to a decrease of Gram-negative bacilli (GNB) and yeasts, although several studies also reported decreased isolates of Gram-positive cocci (GPC). Oropharyngeal and GI colonization significantly decrease after four days of such a regimen, but tracheal decontamination in uncertain. Several studies recognized an emergence of GPC during or after SDD and resistance occurrence in GNB (especially against aminoglycosides). Recolonization occurs rapidly, about 4 to 8 days after the discontinuation of SDD.SDD decreases significantly the nosocomial infections, especially Gram-negative pneumonia. This benefit is most obvious in trauma patients, severely burned patients and after orthopic liver transplantation. Several studies reported a significant decrease in the overall rate of infections, especially extrapulmonary infections, including blood, urinary tract, wounds, abdominal, and catheter related infections. Despite a major decrease in infection rates with SDD, most studies did not show lowered mortality rates. Several studies have reported a reduced mortality rate in selected patient subgroups (trauma patients, ICU stay longer than seven days…). Meta-analyses showed contradictory results. SDD decreases neither the length of stay in the ICU nor the number of days on ventilator. SDD has been used to control nosocomial outbreaks of colonization and infection with multiresistant GNB in ICU, but the results are controversial. In situations leading to MOF and sepsis, as in severe burns, haemorrhagic shock and in endotoxic shock, gut bacteria, especially Enterobacteriaceae, have been demonstrated to translocate into the peritoneal cavity, mesenteric lymph nodes, liver and spleen, finally causing septicaemia. SDD could prevent from gut-originating sepsis by selective elimination of aerobic flora and endotoxin inactivation in the faeces. However these data have been obtained only in rats. The overall cost/effectiveness ratio of SDD use in ICU patients has not been accurately evaluated. In some studies, SDD was associated with a decrease in overall parenteral antibiotic use. In a French multicenter trial, the total costs of antimicrobial agents were 2.2 times higher in ICU patients receiving SDD antibiotics. Therefore additional research is required before SDD regimens can be recommended for routine use in ICU patients. Subpopulations of ICU patients, such as trauma patients may benefit from SDD, but further studies have still to demonstrate the effect of SDD on mortality rate. Research should also be undertaken to determine the effects of SDD on bacterial resistance patterns.